Segment Information and Concentrations

9 Months Ended

12 Months Ended

Mar. 31, 2021

Jun. 30, 2020

Segment Reporting [Abstract]

Segment Information and Concentrations

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems Operations”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Three Months Ended March 31, 2021:
Revenues	$	2,365,700	$	142,900		$	-		$	2,508,600
Foreign Sales		942,200		102,600					1,044,800
Income (Loss) From Operations		774,600		(1,722,200	)		(911,200	)		(1,858,800	)
Assets		5,979,400		1,281,200			6,639,700			13,900,300
Long-Lived Asset Expenditures		18,600		92,100			-			110,700
Depreciation and Amortization		30,000		16,700			-			43,700

Approximately $124,600 included in Assets relates to discontinued operations.

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Three Months Ended March 31, 2020:
Revenues	$	1,800,700	$	335,500		$	-		$	2,136,200
Foreign Sales		743,000		335,000			-			1,078,000
Income (Loss) From Operations		138,800		(193,100	)		(180,700	)		(235,000	)
Assets		5,229,700		1,647,800			2,042,400			8,919,900
Long-Lived Asset Expenditures		4,900		11,700			-			16,600
Depreciation and Amortization		29,600		11,000			300			40,900

Approximately $1,227,900 included in Assets relates to discontinued operations, and $300 in depreciation and amortization relates to discontinued operations.

Approximately 55% and 49% of total benchtop laboratory equipment sales (52% and 37% of total revenues) for the three months ended March 31, 2021 and 2020, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 20% and 24% of total benchtop laboratory equipment sales (19% and 18% of total revenues) were derived from the Torbal Scales Division for the three months ended March 31, 2021 and 2020, respectively.

For the three months ended March 31, 2021 and 2020, respectively, three customers accounted for approximately 26% and 16% of net sales of the Benchtop Laboratory Equipment Operations (25% and 12% of the Company’s total revenues).

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Nine Months Ended March 31, 2021:
Revenues	$	6,803,300	$	441,800		$	-		$	7,245,100
Foreign Sales		2,724,800		395,000			-			3,119,800
Income (Loss) From Operations		1,727,000		(2,996,300	)		(1,029,600	)		(2,298,900	)
Assets		5,979,400		1,281,200			6,639,700			13,900,300
Long-Lived Asset Expenditures		54,100		170,800			-			224,900
Depreciation and Amortization		79,700		46,500			500			126,700

Approximately $124,600 included in Assets relates to discontinued operations, and $500 in depreciation and amortization relates to discontinued operations.

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Nine Months Ended March 31, 2020:
Revenues	$	5,320,300	$	914,200		$	-		$	6,234,500
Foreign Sales		1,996,400		913,700			-			2,910,100
Income (Loss) From Operations		331,300		(209,400	)		(180,700	)		(58,800	)
Assets		5,229,700		1,647,800			2,042,400			8,919,900
Long-Lived Asset Expenditures		26,800		31,300			-			58,100
Depreciation and Amortization		90,900		31,500			900			123,300

Approximately $1,227,900 included in Assets relates to discontinued operations, and $900 in depreciation and amortization relates to discontinued operations.

Approximately 51% and 45% of total benchtop laboratory equipment sales (47% and 36% of total revenues) for the nine months ended March 31, 2021 and 2020, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 23% and 27% of total benchtop laboratory equipment sales (21% and 21% of total revenues) were derived from the Torbal Scales Division for the nine months ended March 31, 2021 and 2020, respectively.

For the nine months ended March 31, 2021 and 2020, three customers accounted for approximately 23% and 17% of net sales of the Benchtop Laboratory Equipment Operations (21% and 13% of the Company’s total revenues), respectively.

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate and Other			Consolidated
June 30, 2020:
Revenues	$	6,783,600	$	1,000,800		$	-		$	7,784,400
Foreign Sales		2,589,800		1,000,400			586,500			4,176,700
Income (Loss) From Operations		449,700		(727,500	)		(385,700	)		(663,500	)
Assets		12,232,600		546,100			2,018,700			14,797,400
Long-Lived Asset Expenditures		36,000		40,700			-			76,700
Depreciation and Amortization		116,900		42,700			1,300			160,900

	Benchtop Laboratory Equipment		Bioprocessing Systems		Corporate and Other		Consolidated
June 30, 2019:
Revenues	$	7,078,800	$	1,306,100	$	-	$	8,384,900
Foreign Sales		2,680,300	$	1,301,200		1,102,300		5,083,800
Income (Loss) From Operations		449,800		365,000		91,900		906,700
Assets		5,280,700		790,100		2,205,200		8,276,000
Long-Lived Asset Expenditures		194,500		15,700		2,200		212,400
Depreciation and Amortization		217,800		38,500		1,000		257,300